BioAtla(BCAB.US)

Last Updated 19:00:00 ET
longbridge loading

Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

TradingView·
US
BCAB
-0.14%
US
CNTX
+7.62%
TradingView·
US
BCAB
-0.14%
US
CNTX
+7.62%

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

StockTitan·
US
CNTX
+7.62%
US
BCAB
-0.14%
StockTitan·
US
CNTX
+7.62%
US
BCAB
-0.14%

NUWE Q1'26 Earnings: EPS estimate is (1.00) USD

TradingView·
US
NUWE
+0.72%
TradingView·
US
NUWE
+0.72%

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga_article·
US
TRVI
+2.02%
US
ADVB
-6.98%
US
SCNI
+4.00%
benzinga_article·
US
TRVI
+2.02%
US
ADVB
-6.98%
US
SCNI
+4.00%

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga_article·
US
CDNA
+1.99%
US
VVOS
-0.88%
US
EUDA
-2.72%
benzinga_article·
US
CDNA
+1.99%
US
VVOS
-0.88%
US
EUDA
-2.72%

NCAB Group Sets April 23 Date for First-Quarter 2026 Results Presentation

Tip Ranks·
US
XBI
+0.81%
US
BBH
+0.64%
US
PBE
+0.35%
Tip Ranks·
US
XBI
+0.81%
US
BBH
+0.64%
US
PBE
+0.35%

NCAB Group Calls 2026 AGM With Expanded Voting Options for Shareholders

Tip Ranks·
US
IBBQ
+0.82%
US
LABU
+2.48%
US
BIB
+1.41%
Tip Ranks·
US
IBBQ
+0.82%
US
LABU
+2.48%
US
BIB
+1.41%

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga_article·
US
PBE
+0.35%
US
RGC
-1.42%
US
XLV
+0.69%
benzinga_article·
US
PBE
+0.35%
US
RGC
-1.42%
US
XLV
+0.69%
© 2026 Longbridge｜Disclaimer